Recently, the well-defined proinflammatory C5a-C5aR pathway has been targeted for pharmacological therapy via inhibition of C5 cleavage, C5a blocking antibodies or C5aR antagonists for treatment of sepsis, cardiovascular diseases, autoimmune disorders, asthma, and psoriasis [18, 19]. The gene discussed is C5; the disease is cardiovascular disorder.